Global Adrenocortical Carcinoma Treatment Market

 

Global Adrenocortical Carcinoma Treatment Market size was valued US$ XX Bn. in 2019 and the total revenue is expected to grow at 4.2% from 2019 to 2027, reaching nearly US$ XX Bn.

 

 

 

Global Adrenocortical Carcinoma Treatment Market

 

To know about the Research Methodology :- Request Free Sample Report

 

The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

 

An adrenocortical carcinoma (ACC) is a deadly form of cancer that arises from the adrenal cortex, i.e., the outer coat of the adrenal gland. ACC is rare and aggressive and demands a multidisciplinary approach towards management and treatment. According to the U.S. National Library of Medicine, the generally 5-year mortality rate is prevalent in 75 to 90% of patients, while, the average time of survival from the diagnosis is nearly 14.5 months.

 

The most common symptoms of ACC include hypertension, abdominal pain, weight gain, and frequent urination, which are mostly because of tumours causing extra secretion of hormones from the adrenal glands. Mitotane is the only drug approved by the European Medicine Executive Agency (EMEA) and the US Food and Drug Administration (FDA) for the treatment of metastatic adrenocortical carcinoma. As per the study by HealthLine Media, 2017, approximately 5-10% of the adrenal tumours are malignant. A wide number of imaging devices are used for diagnoses of the disease, which contains MRI, CT scan, MIBG Scan, and PET scan thus helping for faster disease identification that aids the doctors to decide for further treatments.

 

The MMR report contains a detailed study of factors that will drive and restrain the growth of the adrenocortical carcinoma treatment market. The number of clinical trials is growing for different chemotherapeutics by many manufacturers and organizations. Such as, Millendo Therapeutics Company initiated the Phase-1 trial for ATR-101 in 2013 to treat ACC. Similarly, in March 2018, the University of Colorado Anschutz Medical Campus offered new models to test promising treatments and identify genetic targets in ACC at the ENDO Conference, therefore exploring new therapeutic options for the patients. However, less awareness and high costs involved in the treatment are hampering the adrenocortical carcinoma treatment market globally.

 

By type of cancer, the localized adrenocortical carcinoma segment was valued at US$ XX.05 million in 2019 and is expected to reach a value of US$ XX.10 million by 2027, with a CAGR of XX% during the forecast period because of it’s the most common type with a high occurrence rate. Likewise, the report will provide an accurate prediction of the contribution of the various segments to the growth of the adrenocortical carcinoma treatment market size.

North America’s adrenocortical carcinoma treatment market was valued at US$ XX.11 Mn. in 2019 and is expected to reach a value of US$ XX.09 Mn by 2027, with a CAGR of XX% during the forecast period. The US represents the largest market for ACC followed by which is Canada. In the EU, Germany, France, and the U.K. hold the major share of adrenocortical cancer treatment market.

 

Latin America is expected to gain significant traction during 2019-2027, thanks to a higher incidence rate of the condition in Brazil. As per the Endocrine Society, 2014, the incidence during childhood is 2.9 to 4.2 per million yearly in Brazil compared with an estimated incidence of 0.2 to 0.3 per million children per year globally.

 

The objective of the report is to present a comprehensive analysis of the Global Adrenocortical Carcinoma Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Adrenocortical Carcinoma Treatment Market dynamics, structure by analyzing the market segments and projects the Global Adrenocortical Carcinoma Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Adrenocortical Carcinoma Treatment Market make the report investor’s guide.

Scope of the Global Adrenocortical Carcinoma Treatment Market: Inquire before buying

 

Global Adrenocortical Carcinoma Treatment Market, By Type of Cancer

 

  • Localized Adrenocortical Carcinoma
  • Metastatic Adrenocortical Carcinoma

Global Adrenocortical Carcinoma Treatment Market, By Treatment

 

  • Radiation Therapy
  • Interventional Therapy
  • Systemic Therapy
  • Others

Global Adrenocortical Carcinoma Treatment Market, By End User

 

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Cancer Research Institutes

Global Adrenocortical Carcinoma Treatment Market, By Region

 

  • Asia Pacific
  • North America
  • Europe
  • South America
  • Middle East & Africa

Key players operating in Global Adrenocortical Carcinoma Treatment Market

 

  • ArQule, Inc.
  • Bristol-Myers Squibb Company
  • EnGeneIC Ltd.
  • Exelixis, Inc.
  • Merck KGA
  • Digirad Corporation
  • HRA Pharma
  • Mylan N.V.
  • Millendo Therapeutics
  • Fresenius Kabi AG
  • NeuroLogica Corp.
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Ltd
  • Sinovision Technologies (Beijing)
  • Fresenius Kabi AG

For More Information Vist : https://www.maximizemarketresearch.com/market-report/global-adrenocortical-carcinoma-treatment-market/66037/

Report Is Submitted By : Maximize Market Research Company

 
Customization of the report:

 

 

 

 

Maximize Market Research of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

 

 

About Maximize Market Research:

 

 

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comments are closed